Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction ( <scp> DAPA‐VO <sub>2</sub> </scp> ): a randomized clinical trial-Reference-Cited by-同舟云学术

Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction ( DAPA‐VO ₂ ): a randomized clinical trial

Published:2022-06-06 Issue:10 Volume:24 Page:1816-1826
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European J of Heart Fail

Author:

Palau Patricia¹,Amiguet Martina²,Domínguez Eloy²,Sastre Clara¹,Mollar Anna¹,Seller Julia³,Garcia Pinilla Jose Manuel⁴⁵,Larumbe Ainoha³,Valle Alfonso³,Gómez Doblas Juan Jose⁴⁵,de la Espriella Rafael¹,Miñana Gema¹⁵,Mezcua Ainhoa Robles⁴⁵,Santas Enrique¹,Bodí Vicent¹⁵,Sanchis Juan¹⁵,Pascual‐Figal Domingo⁶⁷,Górriz Jose Luis⁸,Baýes‐Genís Antonio⁵⁹¹⁰,Núñez Julio¹⁵,Palau Patricia,Amiguet Martina,Domínguez Eloy,Sastre Clara,Mollar Anna,Seller Julia,Pinilla Jose Manuel Garcia,Larumbe Ainoha,Valle Alfonso,Doblas Juan Jose Gómez,de la Espriella Rafael,Miñana Gema,Mezcua Ainhoa Robles,Santas Enrique,Bodí Vicent,Sanchis Juan,Pascual‐Figal Domingo,Górriz Jose Luis,Baýes‐Genís Antonio,Civera Jose,Conesa Adriana,Zakarne Rim,Rubio Clara Jiménez,Pérez Cabeza Alejandro I.,Expósito Arancha Díaz,Carmona José David Martínez,Morales Manuel Luna,Zafra Sánchez Francisco J.,Trujillo Ángel Montiel,Climent Herminio Morillas,Núñez Julio,

Affiliation:

1. Cardiology Department, Hospital Clínico Universitario de Valencia Universitat de València, INCLIVA Valencia Spain

2. Fisabio Universitat Jaume I Castellón Spain

3. Cardiology Department Hospital de Denia Alicante Spain

4. Cardiology Department Hospital Universitario Virgen de la Victoria, IBIMA Málaga Spain

5. CIBER Cardiovascular Madrid Spain

6. Cardiology Department Hospital Universitario Virgen de la Arrixaca Murcia Spain

7. Centro Nacional de Investigaciones Cardiovasculares (CNIC) Madrid Spain

8. Nephrology Department Hospital Clínico Universitario de Valencia, Universitat de València, INCLIVA Valencia Spain

9. Department and Heart Failure Unit Hospital Universitari Germans Trias i Pujol Badalona Spain

10. Universitat Autònoma de Barcelona Barcelona Spain

Funder

AstraZeneca

INCLIVA Institute for Health Research

Spanish Clinical Research Network

CIBER

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2560

Reference20 articles.

1. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Heidenreich PA;Circulation,2022

2. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

3. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

4. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction

5. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effect of sodium–glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: Systematic review and meta‐analysis;European Journal of Heart Failure;2024-01-18

2. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status;JACC: Heart Failure;2023-11

3. SGLT2 Inhibitors and Iron;JACC: Heart Failure;2023-11

4. Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin;Journal of Clinical Medicine;2023-10-27

5. Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure;Nature Cardiovascular Research;2023-10-26